Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of Regen BioPharma Inc from 30 Sep 2021 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Regen BioPharma Inc quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 30 Sep 2021 to 31 Dec 2025.
  • Regen BioPharma Inc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Dec 2025 was $64,977, a 11084% decline year-over-year.
  • Regen BioPharma Inc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2025 was $68,839.
  • Regen BioPharma Inc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $120,321, a 272% decline from 2023.
  • Regen BioPharma Inc annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $69,833.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

Regen BioPharma Inc Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $64,977 -$64,396 -11084% 01 Oct 2025 31 Dec 2025 10-Q 13 Feb 2026 2026 Q1
Q4 2024 $581 -$4,041 -117% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2026 2026 Q1
Q4 2023 $3,460 01 Oct 2023 31 Dec 2023 10-Q 16 May 2025 2025 Q1

Regen BioPharma Inc Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $68,839 +$189,160 01 Oct 2024 30 Sep 2025 10-K 30 Dec 2025 2025 FY
2024 $120,321 -$190,154 -272% 01 Oct 2023 30 Sep 2024 10-K 30 Dec 2025 2025 FY
2023 $69,833 +$745,790 01 Oct 2022 30 Sep 2023 10-K 13 May 2025 2024 FY
2022 $675,957 -$1,403,119 -193% 01 Oct 2021 30 Sep 2022 10-K 15 Nov 2022 2022 FY
2021 $727,162 01 Oct 2020 30 Sep 2021 10-K 15 Nov 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.